202 related articles for article (PubMed ID: 31181320)
21. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
22. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.
Chen E; Li E; Liu H; Zhou Y; Wen L; Wang J; Wang Y; Ye L; Liang T
Int J Biol Sci; 2021; 17(3):781-795. PubMed ID: 33767588
[TBL] [Abstract][Full Text] [Related]
23. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
[TBL] [Abstract][Full Text] [Related]
24. Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells.
Qiu W; Wu J; Walsh EM; Zhang Y; Chen CY; Fujita J; Xiao ZX
Oncogene; 2008 Jul; 27(29):4034-43. PubMed ID: 18332869
[TBL] [Abstract][Full Text] [Related]
25. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma.
Endo K; Ueda T; Ohta T; Terada T
Liver; 2000 Jun; 20(3):209-15. PubMed ID: 10902970
[TBL] [Abstract][Full Text] [Related]
26. Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation.
Zhang YY; Zhou LM
Biochem Biophys Res Commun; 2012 Jun; 423(1):26-31. PubMed ID: 22609775
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
28. A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance.
Wang W; Hu B; Qin JJ; Cheng JW; Li X; Rajaei M; Fan J; Yang XR; Zhang R
Genes Dis; 2019 Dec; 6(4):419-430. PubMed ID: 31832522
[TBL] [Abstract][Full Text] [Related]
29. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
[TBL] [Abstract][Full Text] [Related]
30. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
31. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma.
Qiu SJ; Ye SL; Wu ZQ; Tang ZY; Liu YK
J Cancer Res Clin Oncol; 1998; 124(5):253-8. PubMed ID: 9645455
[TBL] [Abstract][Full Text] [Related]
32. p53-dependent upregulation of miR-16-2 by sanguinarine induces cell cycle arrest and apoptosis in hepatocellular carcinoma.
Zhang B; Wang X; Deng J; Zheng H; Liu W; Chen S; Tian J; Wang F
Cancer Lett; 2019 Sep; 459():50-58. PubMed ID: 31163195
[TBL] [Abstract][Full Text] [Related]
33. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
34. Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma.
Koom WS; Park SY; Kim W; Kim M; Kim JS; Kim H; Choi IK; Yun CO; Seong J
J Radiat Res; 2012; 53(2):202-10. PubMed ID: 22510592
[TBL] [Abstract][Full Text] [Related]
35. Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.
Yao JY; Xu S; Sun YN; Xu Y; Guo QL; Wei LB
Acta Pharmacol Sin; 2022 Apr; 43(4):1033-1045. PubMed ID: 34188177
[TBL] [Abstract][Full Text] [Related]
36. Voltage-gated sodium channels β3 subunit promotes tumorigenesis in hepatocellular carcinoma by facilitating p53 degradation.
Li S; Han J; Guo G; Sun Y; Zhang T; Zhao M; Xu Y; Cui Y; Liu Y; Zhang J
FEBS Lett; 2020 Feb; 594(3):497-508. PubMed ID: 31626714
[TBL] [Abstract][Full Text] [Related]
37. Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells.
Patra T; Meyer K; Ray RB; Kanda T; Ray R
Cell Death Dis; 2021 Nov; 12(11):1073. PubMed ID: 34759291
[TBL] [Abstract][Full Text] [Related]
38. A GYS2/p53 Negative Feedback Loop Restricts Tumor Growth in HBV-Related Hepatocellular Carcinoma.
Chen SL; Zhang CZ; Liu LL; Lu SX; Pan YH; Wang CH; He YF; Lin CS; Yang X; Xie D; Yun JP
Cancer Res; 2019 Feb; 79(3):534-545. PubMed ID: 30584071
[TBL] [Abstract][Full Text] [Related]
39. NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity.
Li Q; Liu X; Jin K; Lu M; Zhang C; Du X; Xing B
BMC Cancer; 2017 Aug; 17(1):605. PubMed ID: 28859621
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
